Osteopromotion with synthetic oligopeptide-coated bovine bone mineral in vivo.
BACKGROUND
Recombinant human bone morphogenetic protein (rhBMP)-2 has been shown to stimulate significant regeneration of alveolar bone and cementum in periodontal defects clinically. The aim of this study was to evaluate the osteopromotive effect of oligopeptide domain-coated bovine bone mineral granules in a rabbit calvarial defect model.


METHODS
The peptide-coated bovine bone was fabricated by incubating the graft material in a solution of oligopeptide domain. The cell attachment and proliferation were measured in vitro. Peptide-coated (test group) or uncoated (control group) bone minerals were implanted into 10-mm calvarial defects in rabbits, and the animals were sacrificed at 1, 2, or 4 weeks post-surgery.


RESULTS
The cells grown with peptide-coated bone showed significantly higher proliferation activity at all times compared to cells grown with peptide-uncoated bone mineral. At 2 weeks post-surgery, the control wounds showed a limited amount of osteoid formation in a centripetal pattern around the grafted bone, but the oligopeptide domain-coated grafted bone had formed new bone around the grafted area. At 4 weeks post-surgery, the control sites showed increased new bone formation, but they still showed a significant difference from the peptide-coated bone-implanted sites.


CONCLUSIONS
At 2 and 4 weeks, accelerated new bone formation was observed within the experimental sites compared to control groups. The use of deproteinized bovine bone combined with a synthetic oligopeptide seems to be a more beneficial material for bone regeneration in the early healing period.
Park
Jun-Beom
JB
Department of Periodontology, School of Dentistry, Seoul National University, Seoul, Korea.
Lee
Jue-Yeon
JY
Park
Ho-Nam
HN
Seol
Yang-Jo
YJ
Park
Yoon-Jeong
YJ
Rhee
Sang-Hoon
SH
Lee
Sang-Cheol
SC
Kim
Kyoung-Hwa
KH
Kim
Tae-Il
TI
Lee
Yong-Moo
YM
Ku
Young
Y
Rhyu
In-Chul
IC
Han
Soo-Boo
SB
Chung
Chong-Pyoung
CP
D016475:3T3 Cells; D000704:Analysis of Variance; D000818:Animals; D001857:Bone Matrix / Q000637:transplantation*; D055396:Bone Morphogenetic Protein 2; D052004:Bone Morphogenetic Protein Receptors / Q000502:physiology*; D019485:Bone Morphogenetic Proteins / Q000494:pharmacology; D001861:Bone Regeneration / Q000187:drug effects*; D002417:Cattle; D002448:Cell Adhesion / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D020099:Coated Materials, Biocompatible / Q000494:pharmacology*; D006801:Humans; D051379:Mice; D009842:Oligopeptides / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects; D011817:Rabbits; D011994:Recombinant Proteins / Q000494:pharmacology; D012886:Skull / Q000601:surgery; D016212:Transforming Growth Factor beta / Q000494:pharmacology
D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D020099:Coated Materials, Biocompatible; D009842:Oligopeptides; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D052004:Bone Morphogenetic Protein Receptors